Direct monthly highly active antiretroviral therapy supply – a method to increase patient's adherence and outcome. Experience of one AIDS centre in Israel

Abstract

In Israel, antiretroviral therapy (ART) is available (at local pharmacies) without cost. Nevertheless, poor adherence, especially of immigrants from Africa, leads to a high rate of treatment failures. Our study looked whether direct monthly ART supply in our AIDS centre has an effect on adherence and outcome. A total of 385 HIV (clade C) immigrants from Africa that were treated with ART for >2 years prior to the initiation of the study were evaluated. During the first 2 years, ART medications were supplied by local pharmacies. Thereafter (next 2 years), all patients received medications, monthly at our centre. Adherence, immunological (CD4) and virological (VL) outcome at the end of the two study periods were determined. At baseline, only 75% of the patients attended more than 90% of scheduled visits with 57% treatment adherence. Virological failure (VL >40 copies/ml) was observed in 53% of the patients. As a result of our intervention (2 years of direct monthly ART supply), visits and treatment adherence significantly increased (90% and 84%, respectively; p < 0.001). Concomitantly, virological failure rate significantly dropped to 28% (p < 0.001). Direct monthly supply of ART is a relatively low-cost mode to improve patient's adherence and immunological/virological outcomes.

Keywords

HIV/AIDS adherence highly active antiretroviral therapy direct observed therapy Ethiopian clade C

Get full access to this article

View all access options for this article.

References

Dieffenbach

Fauci

. Thirty years of HIV and AIDS: future challenges and opportunities. Ann Intern Med 2011; 154: 766–771.

World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision, http://www.who.int/hiv/pub/arv/adult2010/en/index.html (accessed 21 September 2010).

Deeks

Perry

. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection. Drugs 2010; 70: 2315–2338.

Gulick

. Antiretroviral treatment 2010: progress and controversies. J Acquir Immune Defic Syndr 2010; 55: S43–S48.

Amico

Harman

Johnson

. Efficacy of antiretroviral therapy adherence interventions: A research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr 2006; 41: 285–297.

Ingersoll

Cohen

. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 2008; 31: 213–224.

Donnan

MacDonald

Morris

. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabetic Med 1996; 19: 270–284.

Grant

Devita

Singer

. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 2003; 26: 1408–1412.

Chapman

Benner

Petrilla

. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Int Med 2005; 165: 1147–1152.

10.

Ammassari

Starace

Aloisi

. Medication adherence among HIV+ adults: Effects of cognitive dysfunction and regimen complexity. Neurology 2003; 61: 723–724.

11.

Conway

. The role of adherence to antiretroviral therapy in the management of HIV infection. J Acquir Immune Defic Syndr 2007; 45: S14–S18.

12.

Davies

. The role of DOTS in tuberculosis treatment and control. Am J Respir Med 2003; 2: 203–209.

13.

Fischl M, Castro J, Monroig R, et al. Impact of directly observed therapy on long-term outcomes in HIV clinical trials. In: The 8th conference on retroviruses and opportunistic infection, 2001 Abstract number 528.

14.

Mitty

Stone

Sands

. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis 2002; 34: 984–990.

15.

Elbirt

Asher

Broda

. Israeli-migrants from Sub-Saharan Africa (Ethiopia) and HIV: Medical and Social issues. The experience of one major HIV center. Int Public Health J 2010; 2: 329–337.

16.

Branson

. State of the art for diagnosis of HIV infection. Clin Infect Dis 2007; 45: S221–S225.

17.

Kantor

. Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acid Res 2001; 2: 296–9.

18.

Flandre

Peytavin

Meiffredy

. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial. Antiviral Therapy 2002; 7: 113–121.

19.

Simoni

Pearson

Pantalone

. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. J Acquir Immune Defic Syndr 2006; 43: S1, S23–S35.

20.

Cohen

Chen

McCauley

. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493–505.

21.

Fogarty

Roter

Larson

. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Counsel 2002; 46: 93–108.

22.

Murphy

Roberts

Martin

. Barriers to antiretroviral adherence among HIV-infected adults. AIDS Patient Care STDs 2000; 14: 47–58.

23.

Paterson

Swindells

Mohr

. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Int Med 2000; 133: 21–30.

24.

Wohl

Stephenson

Golin

. Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates. Clin Infect Dis 2003; 36: 1572–1576.

25.

Peterson

Takiya

Finley

. Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm 2003; 60: 657–665.